Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE, Lam W, McBride K, Wride K, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB, Habermann TM. Wiernik PH, et al. Among authors: pietronigro d. J Clin Oncol. 2008 Oct 20;26(30):4952-7. doi: 10.1200/JCO.2007.15.3429. Epub 2008 Jul 7. J Clin Oncol. 2008. PMID: 18606983 Clinical Trial.
An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma.
Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA, Bouabdallah R, Haioun C, Tilly H, Guo P, Pietronigro D, Ervin-Haynes AL, Czuczman MS. Witzig TE, et al. Among authors: pietronigro d. Ann Oncol. 2011 Jul;22(7):1622-1627. doi: 10.1093/annonc/mdq626. Epub 2011 Jan 12. Ann Oncol. 2011. PMID: 21228334 Free article. Clinical Trial.
Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma.
Habermann TM, Lossos IS, Justice G, Vose JM, Wiernik PH, McBride K, Wride K, Ervin-Haynes A, Takeshita K, Pietronigro D, Zeldis JB, Tuscano JM. Habermann TM, et al. Among authors: pietronigro d. Br J Haematol. 2009 May;145(3):344-9. doi: 10.1111/j.1365-2141.2009.07626.x. Epub 2009 Feb 24. Br J Haematol. 2009. PMID: 19245430 Free article. Clinical Trial.
The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin.
Czuczman MS, Vose JM, Witzig TE, Zinzani PL, Buckstein R, Polikoff J, Li J, Pietronigro D, Ervin-Haynes A, Reeder CB. Czuczman MS, et al. Among authors: pietronigro d. Br J Haematol. 2011 Aug;154(4):477-81. doi: 10.1111/j.1365-2141.2011.08781.x. Epub 2011 Jun 28. Br J Haematol. 2011. PMID: 21707581 Free article. Clinical Trial.
Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma.
Chen C, Reece DE, Siegel D, Niesvizky R, Boccia RV, Stadtmauer EA, Abonour R, Richardson P, Matous J, Kumar S, Bahlis NJ, Alsina M, Vescio R, Coutre SE, Pietronigro D, Knight RD, Zeldis JB, Rajkumar V. Chen C, et al. Among authors: pietronigro d. Br J Haematol. 2009 Jul;146(2):164-70. doi: 10.1111/j.1365-2141.2009.07728.x. Epub 2009 May 26. Br J Haematol. 2009. PMID: 19545290 Free PMC article.
DTI-015 produces cures in T9 gliosarcoma.
Pietronigro D, Drnovsky F, Cravioto H, Ransohoff J. Pietronigro D, et al. Neoplasia. 2003 Jan-Feb;5(1):17-22. doi: 10.1016/s1476-5586(03)80013-1. Neoplasia. 2003. PMID: 12659666 Free PMC article.
25 results